News

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) ...